## **Designing Clinical Trials for Older Adults**

- What has worked
  - Dedicated trials for Older Patients
    - CALGB 49907<sup>1</sup>, MRC Focus 2<sup>2</sup>, Alliance 171601
  - Minimize exclusion criteria: let patient/doctor decide
  - Trials for Vulnerable Patients (Dr. Mohile)
- ➤ What does not work
  - Reminders and other unneeded sensory input

l. DOI: 10.1200/JCO.19.00647

2. DOI: https://doi.org/10.1016/S0140-6736(11)60399-1



## Success: A171601 Alliance

- ➤ Cooperative Group Based (PI: Sedrak NCT03633331)
- ➤ Question: What is the effect on function and toxicity of palbociclib and endocrine therapy in women 70 and older?
- ➤ Problem: In pivotal registration trial only 37 pts >= 65
- Pragmatic trial
- > Funding NCI NCORP
- > Accrual completed using multiple sites
- >A successful prototype for other trails now ongoing.



## Older Adult Relevant Endpoints

- ➤ Expansion Cohort for successful Phase III trials
  - Establish reasonable 95% CI for toxicity in 65 and older
  - Key for new agents
- > Functional change
  - Incorporate the GA or relevant domains
  - Patient reported outcomes
  - Chronic Toxicity: neuropathy, fatigue
- Value: Was it worth it?

